Selected recently evaluated targeted therapies for relapsed/refractory aggressive B-cell NHL
| Class/agent . | Study (reference) . | Phase/design . | N . | ORR, % . | PFS . |
|---|---|---|---|---|---|
| BTK inhibitors | |||||
| Ibrutinib | 11 | 1/2/monotherapy | 80 | 37 (ABC) | 2 mo (ABC) |
| 5 (GCB) | 1.3 mo (GCB) | ||||
| Ibrutinib | 46 | 1/ with buparlisib | 10 | 14 | — |
| BGB-3111 | 47 | 1b/monotherapy | 23 | 61 (DLBCL + MCL) | — |
| PI3K inhibitors | |||||
| Buparlisib | 12,48 | 2/monotherapy | 26 | 12 | 1.8 mo |
| Umbralisib | 49 | 1/with ublituximab and ibrutinib | 6 | 17 | — |
| CUDC-907 | 13 | 1/monotherapy | 25 | 47 | 5.7 mo |
| 1/with rituximab | 12 | 18 | 1.3 mo | ||
| Syk inhibitors | |||||
| Fostamatinib | 15 | 2/monotherapy | 68 | 3 | 7.3 wk |
| TAK-659 | 50 | 1/monotherapy | 69 | 27 | 50 d |
| mTOR inhibitors | |||||
| Vistusertib | 51 | 2/monotherapy and with rituximab | 36 | 5.6 | 1.9 mo |
| Temsirolimus | 16 | 2/monotherapy | 28 | 2.6 mo | |
| Everolimus | 17 | 2/monothereapy | 77 | 30 | 3 mo |
| Other agents | |||||
| Apilimod dimesylate | 19 | 1/monotherapy | 11 | 27 | — |
| Venetoclax | 52 | 1/monotherapy | 34 | 18 | 1 mo |
| Mocetinostat | 20 | 2/monotherapy | 41 | 19 | — |
| Selinexor | 53 | 1/monotherapy | 79 | 31 | — |
| Class/agent . | Study (reference) . | Phase/design . | N . | ORR, % . | PFS . |
|---|---|---|---|---|---|
| BTK inhibitors | |||||
| Ibrutinib | 11 | 1/2/monotherapy | 80 | 37 (ABC) | 2 mo (ABC) |
| 5 (GCB) | 1.3 mo (GCB) | ||||
| Ibrutinib | 46 | 1/ with buparlisib | 10 | 14 | — |
| BGB-3111 | 47 | 1b/monotherapy | 23 | 61 (DLBCL + MCL) | — |
| PI3K inhibitors | |||||
| Buparlisib | 12,48 | 2/monotherapy | 26 | 12 | 1.8 mo |
| Umbralisib | 49 | 1/with ublituximab and ibrutinib | 6 | 17 | — |
| CUDC-907 | 13 | 1/monotherapy | 25 | 47 | 5.7 mo |
| 1/with rituximab | 12 | 18 | 1.3 mo | ||
| Syk inhibitors | |||||
| Fostamatinib | 15 | 2/monotherapy | 68 | 3 | 7.3 wk |
| TAK-659 | 50 | 1/monotherapy | 69 | 27 | 50 d |
| mTOR inhibitors | |||||
| Vistusertib | 51 | 2/monotherapy and with rituximab | 36 | 5.6 | 1.9 mo |
| Temsirolimus | 16 | 2/monotherapy | 28 | 2.6 mo | |
| Everolimus | 17 | 2/monothereapy | 77 | 30 | 3 mo |
| Other agents | |||||
| Apilimod dimesylate | 19 | 1/monotherapy | 11 | 27 | — |
| Venetoclax | 52 | 1/monotherapy | 34 | 18 | 1 mo |
| Mocetinostat | 20 | 2/monotherapy | 41 | 19 | — |
| Selinexor | 53 | 1/monotherapy | 79 | 31 | — |
ABC, activated B cell; GBC, germinal center B cell–like; MCL, mantle cell lymphoma; mTOR, mammalian target of rapamycin; ORR, overall response rate; PFS, progression-free survival; syk, spleen tyrosine kinase.